iboxamycin

Also Known As:

(4S,5aS,8S,8aR)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl)propyl)-4-(2-methylpropyl)-3,4,5,5a,6,7,8,8a-octahydro-2H-oxepino(2,3-c)pyrrole-8-carboxamide

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Ethers: 242
  - Cyclic Ethers: 12
    - Oxepins: 16
      - iboxamycin: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - iboxamycin: 2
  - Oxepins: 16
    - iboxamycin: 2

Experts

1.	Mason, Jeremy D: 2 articles (11/2021 - 01/2021)
2.	Myers, Andrew G: 2 articles (11/2021 - 01/2021)
3.	Pote, Aditya R: 2 articles (11/2021 - 01/2021)
4.	Terwilliger, Daniel W: 2 articles (11/2021 - 01/2021)
5.	Chatman, Kelly: 1 article (11/2021)
6.	Klepacki, Dorota: 1 article (11/2021)
7.	Ladley, Richard Porter: 1 article (11/2021)
8.	Mankin, Alexander S: 1 article (11/2021)
9.	Mitcheltree, Matthew J: 1 article (11/2021)
10.	Pisipati, Amarnath: 1 article (11/2021)

Related Diseases

1.	Gram-Negative Bacterial Infections 11/01/2021 - "Iboxamycin is orally bioavailable, safe and effective in treating both Gram-positive and Gram-negative bacterial infections in mice, attesting to the capacity for chemical synthesis to provide new antibiotics in an era of increasing resistance."
2.	Infections 01/01/2021 - "Implementation of this synthetic strategy has provided ample quantities of iboxamycin to allow for its in vivo profiling in murine models of infection."

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)